KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2016 - 2025)

Teva Pharmaceutical Industries' Total Current Liabilities history spans 17 years, with the latest figure at $13.5 billion for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 5.16% year-over-year to $13.5 billion, compared with a TTM value of $13.5 billion through Dec 2025, up 5.16%, and an annual FY2025 reading of $13.5 billion, up 5.16% over the prior year.
  • Total Current Liabilities for Q4 2025 was $13.5 billion at Teva Pharmaceutical Industries, up from $11.5 billion in the prior quarter.
  • The five-year high for Total Current Liabilities was $13.8 billion in Q3 2024, with the low at $10.4 billion in Q1 2023.
  • Average Total Current Liabilities over 5 years is $12.0 billion, with a median of $11.8 billion recorded in 2021.
  • Year-over-year, Total Current Liabilities surged 32.48% in 2024 and then fell 19.11% in 2025.
  • Tracing TEVA's Total Current Liabilities over 5 years: stood at $11.0 billion in 2021, then rose by 4.01% to $11.5 billion in 2022, then rose by 6.78% to $12.2 billion in 2023, then grew by 4.48% to $12.8 billion in 2024, then grew by 5.16% to $13.5 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Total Current Liabilities are $13.5 billion (Q4 2025), $11.5 billion (Q3 2025), and $11.9 billion (Q2 2025).